References
- Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther 2003;25:1634–53.
- Thomas S, Shandily S, Bharati A, et al. Identification, characterization and quantification of new impurities by LC–ESI/MS/MS and LC-UV methods in rivastigmine tartrate active pharmaceutical ingredient. J Pharm Biomed Anal 2012;57:39–51.
- Shah BM, Misra M, Shishoo CJ, Padh H. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv 2015;22:1–13.
- Tamai I, Tsuji A. Drug delivery through the blood brain barrier. Adv Drug Deliv Rev 1996;19:401–24.
- Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557–64.
- Antuono P, Beyer J. The burden of dementia. A medical and research perspective. Theor Med Bioeth 1999;20:3–13.
- Bodor N, Prokai L, Wu W, et al. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992;257:1698–700.
- Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010;76:189–99.
- Fazila M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012;47:6–15.
- Craparo EF, Pitarresi G, Bondi ML, et al. A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. Macromol Biosci 2008;8:247–59.
- Pagar K, Vavia P. Rivastigmine-loaded l-lactide-depsipeptide polymeric nanoparticles: decisive formulation variable optimization. Sci Pharm 2013;81:865–85.
- Avachat AM, Oswal YM, Gujar KN, Shah RD. Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles. Curr Drug Deliv 2014;11:359–70.
- Shah B, Khunt D, Bhatt H, et al. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci 2015;78:54–66.
- Coti KK, Belowich ME, Liong M, et al. Mechanised nanoparticles for drug delivery. Nanoscale 2009;1:16–39.
- Rashidi L, Vasheghani-Farahani E, Rostami K, et al. Mesoporous silica nanoparticles as a nanocarrier for delivery of vitamin C. Iran J Biotechnol 2013;11:209–13.
- Rashidi L, Vasheghani-Farahani E, Rostami K, et al. Mesoporous silica nanoparticles with different pore sizes for delivery of pH-sensitive gallic acid. Asia-Pacific J Chem Eng 2014;9:845–53.
- Yokoi T, Yoshitake H, Tatsumi T. Synthesis of amino-functionalized MCM-41 via direct co-condensation and post-synthetic grafting methods using mono-, di-, and tri-amino-organoalkoxysilanes. J Mater Chem 2004;14:951.
- Leane MM, Nankervis R, Smith A, Illum L. Use of the ninhydrin assay to measure the release of chitosan from oral solid dosage forms. Int J Pharm 2004;271:241–9.
- Suwalski A, Dabboue H, Delalande A, et al. Accelerated Achilles tendon healing by PDGF gene delivery with mesoporous silica nanoparticles. Biomaterials 2010;31:5237–45.
- Rashidi L, Vasheghani-Farahani E, Soleimani M, et al. A cellular uptake and cytotoxicity properties study of gallic acid-loaded mesoporous silica nanoparticles on Caco-2 cells. Nanopart Res 2014;16:1–14.
- Chang SS, Kibel AS. The role of systemic cytotoxic therapy for prostate cancer. BJU Int 2009;103:8–17.
- Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release 2000;145:182–95.
- Tamilselvan N, Raghavan CV, Balakumar K, Karthik S. Brain targeted delivery of rivastigmine polymeric nanoparticles through oral administration to treat Alzheimer’s disease. Int J Res Pharm Nano Sci 2014;3:536–51.
- Stoddart JF. Mechanised nanoparticles for drug delivery. Nanoscale 2009;1:6–39.